DEF: Titan Pharmaceuticals Seeks Stockholder Approval for Share Issuance, Equity Plan Amendment at Upcoming Annual Meeting

Titan Pharmaceuticals is holding its annual meeting on June 16, 2025, seeking stockholder approval for several key proposals, including a share issuance related to a private placement, an amendment to its equity incentive plan, and the ratification of its independent auditor.

Summary

• Titan Pharmaceuticals will hold its annual meeting of stockholders on June 16, 2025, to vote on several proposals.
• The proposals include electing five directors, approving the issuance of more than 20% of common stock in a private placement, and amending the 2015 Omnibus Equity Incentive Plan.
• Stockholders will also vote to ratify the appointment of Enrome LLP as the independent auditor for the fiscal year ending December 31, 2025.
• There will be non-binding advisory votes on executive compensation and the frequency of future votes on executive compensation.
• The record date for determining stockholders eligible to vote is April 21, 2025.
• The company is using the SEC's Notice and Access model to deliver proxy materials over the internet.
• A quorum of 34% of shares entitled to vote is required for the meeting.
• The board recommends voting for all director nominees, the issuance proposal, the 2015 plan amendment, and the ratification of the auditor appointment.
• The board recommends a two-year frequency for advisory votes on executive compensation.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential for strengthened financial position and growth, there are also concerns about dilution, past financial losses, and the need for additional capital. The sentiment is cautiously optimistic but tempered by significant risks and challenges.

Positives

• Approval of the share issuance proposal would strengthen the company's financial position and growth potential.
• The proposed amendment to the 2015 Equity Incentive Plan is intended to attract, motivate, and retain key employees, directors, advisors and consultants.
• The company is committed to good corporate governance practices, including a clawback policy and an insider trading policy.

Negatives

• If the share issuance proposal is approved, existing stockholders will experience dilution.
• The company has had changes in its executive leadership, including multiple CEO appointments and resignations in recent years.
• The company's audit committee reported that WithumSmith+Brown, PC's audit report contained an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• If the share issuance proposal is not approved, the company may face challenges obtaining financing in the future.
• Failure to meet Nasdaq continued listing requirements could result in delisting, negatively impacting the stock's liquidity and market price.
• The proposed merger with TalenTec Sdn. Bhd. is subject to stockholder approval and other conditions, with no assurance of completion.
• The company has a history of net losses, as indicated in the Pay Versus Performance table.

Future Outlook

The company is focused on obtaining stockholder approval for the proposed share issuance and equity plan amendment to strengthen its financial position and support future growth. The company is also working to complete the proposed merger with TalenTec Sdn. Bhd., which is subject to stockholder approval and other conditions.

Management Comments

• The Board believes that an adequate reserve of shares available for issuance under the 2015 Plan is necessary to enable the Company to attract, motivate, and retain key employees, directors, advisors and consultants through the use of competitive incentives that are tied to stockholder value.
• The Board hereby recommends that our stockholders approve, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of shares of common stock issuable upon conversion of the shares of Series B Preferred Stock, in an amount in excess of 19.99% of the number of shares of the Company's common stock outstanding immediately prior to the issuance of such Series B Preferred Stock, thereby removing the Beneficial Ownership Limitation.

Industry Context

The company's need for additional capital and the proposed merger with TalenTec suggest a challenging financial environment. The company is operating in a competitive market and is seeking to improve its financial position through strategic transactions and equity financing.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the company's reliance on equity financing and the proposed merger suggest that it may be facing challenges in generating revenue and achieving profitability compared to its peers.
• The company's executive compensation practices appear to be in line with industry standards, with a mix of salary, bonus, and equity-based compensation.
• The company's corporate governance practices, including the establishment of audit, compensation, and nominating and governance committees, are consistent with industry best practices.

Management Changes

Corporate Governance

Related Party Transactions

• In July 2023, the company received $250,000 in funding in exchange for the issuance of an unsecured promissory note for that principal amount to David E. Lazar, our former Chief Executive Officer and prior chairman of our Board (the Lazar Promissory Note).
• In August 2023, the company received $500,000 in funding from one of our stockholders, Choong Choon Hau, in exchange for the issuance of a convertible promissory note for that principal amount to Choong Choon Hau (the Hau Promissory Note).
• During the years ended December 31, 2024 and 2023, we made payments related to legal and consulting fees of approximately $13,000 and $109,000, respectively, to a law firm operated by one of our Board members.
• Pursuant to the Settlement Agreement and General and Mutual Release dated April 2, 2024 between us and Mr. Lazar, in the event of a Change in Control (as defined in Mr. Lazars Employment Agreement dated December 14, 2022), we (or any successor entity) agreed to pay to Mr. Lazar a lump-sum amount equal to three percent (3%) of the increased valuation of the surviving corporation resulting from such Change in Control (as determined by either (i) the definitive agreement governing the Change in Control or (ii) the highest market cap of the surviving corporation within the thirty (30) days following the Change in Control), less applicable taxes and withholdings.

Stakeholder Impact

• Approval of the share issuance proposal would result in dilution for existing stockholders.
• The proposed merger with TalenTec could significantly alter the ownership structure of the company.
• Executive compensation decisions impact shareholder value and employee morale.
• The appointment of an independent auditor ensures the integrity of financial reporting.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on June 16, 2025.
• Completion of the private placement with Blue Harbour Asset Management L.L.C-FZ, pending stockholder approval.
• Continued efforts to finalize and complete the proposed merger with TalenTec Sdn. Bhd.
• Preparation and filing of a joint proxy statement/prospectus in respect of the Merger.

Key Dates

Keywords

proxy statement, annual meeting, stockholder vote, share issuance, equity incentive plan, executive compensation, independent auditor, corporate governance, Titan Pharmaceuticals